Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1978485rdf:typepubmed:Citationlld:pubmed
pubmed-article:1978485lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1978485lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:1978485lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:1978485pubmed:dateCreated1990-12-14lld:pubmed
pubmed-article:1978485pubmed:abstractTextVariability in the outcome of treatment with antipsychotic drugs may be due to differences in compliance and to variations in pharmacokinetics and concentration-response relationships at the receptor level. Among the various chemical classes of neuroleptics, the butyrophenones, the phenothiazines, and the thioxanthenes have similar pharmacokinetics, and show larger inter-individual variations in plasma drug levels after oral than after intramuscular doses. Compared to the "classical" neuroleptics, the more water-soluble benzamide derivatives have significantly shorter elimination half-lives, and show smaller inter-patient variations in plasma level: dose ratios at steady state.lld:pubmed
pubmed-article:1978485pubmed:languageenglld:pubmed
pubmed-article:1978485pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978485pubmed:citationSubsetIMlld:pubmed
pubmed-article:1978485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1978485pubmed:statusMEDLINElld:pubmed
pubmed-article:1978485pubmed:issn0065-1591lld:pubmed
pubmed-article:1978485pubmed:authorpubmed-author:DahlS GSGlld:pubmed
pubmed-article:1978485pubmed:issnTypePrintlld:pubmed
pubmed-article:1978485pubmed:volume358lld:pubmed
pubmed-article:1978485pubmed:ownerNLMlld:pubmed
pubmed-article:1978485pubmed:authorsCompleteYlld:pubmed
pubmed-article:1978485pubmed:pagination37-40lld:pubmed
pubmed-article:1978485pubmed:dateRevised2008-2-15lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:meshHeadingpubmed-meshheading:1978485-...lld:pubmed
pubmed-article:1978485pubmed:year1990lld:pubmed
pubmed-article:1978485pubmed:articleTitlePharmacokinetics of antipsychotic drugs in man.lld:pubmed
pubmed-article:1978485pubmed:affiliationInstitute of Medical Biology, University of Tromsø School of Medicine, Norway.lld:pubmed
pubmed-article:1978485pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1978485pubmed:publicationTypeReviewlld:pubmed